Please assess the completion status of the following clinical trial:

Trial Title: Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of ES with age greater than or equal to 14 years and weight greater than or equal to 30 kgs in World Health Organisation (WHO) functional class II and III attending our congenital clinic were invited to participate in the study~Exclusion Criteria:~* WHO class IV,~* congestive heart failure or had PCWP \> 15mmHg,~* left ventricular ejection fraction \<40%,~* atrial fibrillation,~* patent ductus arteriosus,~* complex congenital heart defects,~* restrictive lung disease(total lung capacity \< 70% of predicted), obstructive lung disease ( forced expiratory volume in 1 second \[FEV1\] \< 70% of predicted with FEV1/ Forced vital capacity \[FVC\] \< 60%),~* previously diagnosed coronary artery disease requiring nitrate therapy,~* abnormal biochemical profile and~* hypersensitivity to PDE- 5 inhibitors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tadalafil (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).